Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments.
The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies.
Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, along with more than $1.7 billion in long-only public funds since 2021.
The FLS team includes seven investment partners and over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach, leading to 25 new companies since 2020.
Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics, Mirum Pharmaceuticals, NewAmsterdam Pharma, Tarsus Pharmaceuticals, and Amunix Pharmaceuticals (acquired by Sanofi).
KEY QUOTE:
“We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016. With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs.”
Patrick Heron, Managing Partner at Frazier Life Sciences
